Rubiadin Regulates Bone Metabolism in Ovariectomized Rat Model by Inhibition of osteoclast formation and differentiation
暂无分享,去创建一个
[1] L. Qin,et al. Metabolomics profiling provides valuable insights into the underlying mechanisms of Morinda officinalis on protecting glucocorticoid‐induced osteoporosis , 2019, Journal of pharmaceutical and biomedical analysis.
[2] T. Han,et al. Rubiadin-1-methyl ether from Morinda officinalis How. Inhibits osteoclastogenesis through blocking RANKL-induced NF-κB pathway. , 2018, Biochemical and biophysical research communications.
[3] Xinying Ji,et al. The triptolide‐induced apoptosis of osteoclast precursor by degradation of cIAP2 and treatment of rheumatoid arthritis of TNF‐transgenic mice , 2018, Phytotherapy research : PTR.
[4] M. Rasool,et al. Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF‐&kgr;B signalling pathway , 2018, Life sciences.
[5] Yung-Hyun Choi,et al. Sargassum serratifolium attenuates RANKL-induced osteoclast differentiation and oxidative stress through inhibition of NF-κB and activation of the Nrf2/HO-1 signaling pathway. , 2018, Bioscience trends.
[6] Yu-Ching Lin,et al. Risk factors and quality of life for the occurrence of hip fracture in postmenopausal women , 2018, Biomedical journal.
[7] Chengqi He,et al. Review Effectsof PulsedElectromagnetic Fieldson PostmenopausalOsteoporosis , 2017 .
[8] L. Kiesel,et al. Role of the RANK/RANKL pathway in breast cancer. , 2016, Maturitas.
[9] A. Oryan,et al. Three-Dimensional Porous Gelapin–Simvastatin Scaffolds Promoted Bone Defect Healing in Rabbits , 2015, Calcified Tissue International.
[10] T. Jukić,et al. Digital orthopantomograms in osteoporosis detection: mandibular density and mandibular radiographic indices as skeletal BMD predictors. , 2014, Dento maxillo facial radiology.
[11] I. Kwon,et al. Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species , 2011, Experimental & Molecular Medicine.
[12] T. Han,et al. Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro. , 2011, Chemico-biological interactions.
[13] Xu Feng,et al. Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis , 2010, Expert opinion on therapeutic targets.
[14] F. Otsuka,et al. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling , 2010, Regulatory Peptides.
[15] J. Eisman,et al. Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] J. Pelletier,et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. , 2009, Rheumatology.
[17] C. Zheng,et al. Antiosteoporotic Activity of Anthraquinones from Morinda officinalis on Osteoblasts and Osteoclasts , 2009, Molecules.
[18] Ting Han,et al. Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. , 2008, Journal of ethnopharmacology.
[19] M. Heymann,et al. OPG, RANK and RANK ligand expression in thyroid lesions , 2008, Regulatory Peptides.
[20] M. Padrines,et al. Key roles of the OPG–RANK–RANKL system in bone oncology , 2007, Expert review of anticancer therapy.
[21] L. Notarangelo,et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis , 2000, Nature Genetics.
[22] S. Dixon,et al. Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway. , 2008, Bone.